Article Text

Download PDFPDF
Baricitinib for juvenile idiopathic arthritis: a monocentric case series
  1. Ilaria Maccora1,2,
  2. Teodoro Oliverio3,
  3. Ilaria Pagnini1,
  4. Edoardo Marrani1,
  5. Maria Vincenza Mastrolia1,
  6. Gabriele Simonini1,2
  1. 1Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy
  2. 2NeuroFARBA Department, University of Florence, Firenze, Italy
  3. 3School of Human Health Science, University of Florence, Firenze, Italy
  1. Correspondence to Dr Ilaria Maccora, Rheumatology Unit, Meyer Children's Hospital IRCCS, Florence, Italy; ilamaccora{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Antitumour necrosis factor α drugs dramatically changed the prognosis of juvenile idiopathic arthritis (JIA), the most common chronic rheumatic disease in childhood. Promising results from janus kinase inhibitors (JAKi), small molecules orally administered that inhibit specific receptor of the JAK family, are emerging. Tofacitinib, a non-selective JAKi, has shown an excellent efficacy in a recent randomised controlled trial(RCT) for polyarticular JIA.1

Baricitinib, a selective JAK 1 and JAK 2 inhibitor, resulted superior to placebo and adalimumab (ADA) in treating rheumatoid arthritis.2 Data are, however, scarce in JIA, and results from ongoing RCTs are still pending(NCT03773978, NCT03773965, NCT04088409).

We, here, report four patients with polyarticular JIA children, fulfilling ILAR criteria, treated with baricitinib (4 mg) (table 1). All patients received an extensive infectious workup before drug starting.

View this table:
Table 1

Schematic presentation of demographic, clinical and laboratory findings of this cohort of patients

Patient 1 is a 13-year-old Caucasian female with psoriatic arthritis, who previously obtained remission combining methotrexate (MTX) and ADA as methotrexate …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors IM and TO wrote the first draft of the manuscript. IM and GS conceptualised the study and review the final version of the manuscript. IP, EM and MVM revised the final draft of the manuscript. All the authours followed the patients during their follow-up.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.